Prognosis
Russia Delays Approving Chinese Vaccine to Favor Homegrown Shots
- CanSino’s local partner had hoped for authorization in January
- Russia has developed three of its own Covid-19 vaccines
Boxes of Sputnik V Covid-19 vaccines at the cargo terminal at Sheremetyevo International Airport in Moscow.
Photographer: Andrey Rudakov/BloombergThis article is for subscribers only.
Russian officials have slowed the authorization of China’s CanSino Biologics Inc.’s Covid-19 vaccine, the only foreign inoculation that is undergoing domestic testing, as they’re confident they can vaccinate the public using homegrown shots.
Registering the single-shot vaccine is taking so long because local authorities are prioritizing Russian-developed inoculations, according to three people familiar with the situation who asked not to be named because the information is not public.